 | • レポートコード：MRC2303G002 • 出版社/出版日：Mordor Intelligence / 2023年2月 • レポート形態：英文、PDF、114ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医薬品 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の市場調査書では、世界の脱毛症治療薬（脱毛）市場について広く調査・分析を行い、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、疾患種類別（男性型脱毛症、円形脱毛症、瘢痕性脱毛症、牽引性脱毛症、完全脱毛症）分析、性別（男性、女性）分析、投与経路別（経口、外用、注射）分析、流通チャネル別（病院、小売薬局、オンライン薬局）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来動向などの項目について記載しています。並びに、本書に記載されている企業情報には、Aclaris Therapeutics Inc.、Cipla Inc.、Concert Pharmaceuticals Inc.、Daiichi Sankyo Inc.、GlaxoSmithKline PLC、HCell Inc.、Johnson & Johnsonなどが含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の脱毛症治療薬（脱毛）市場規模：疾患種類別 - 男性型脱毛症における市場規模 - 円形脱毛症における市場規模 - 瘢痕性脱毛症における市場規模 - 牽引性脱毛症における市場規模 - 完全脱毛症における市場規模 ・世界の脱毛症治療薬（脱毛）市場規模：性別 - 男性における市場規模 - 女性における市場規模 ・世界の脱毛症治療薬（脱毛）市場規模：投与経路別 - 経口型脱毛症治療薬（脱毛）の市場規模 - 外用型脱毛症治療薬（脱毛）の市場規模 - 注射型脱毛症治療薬（脱毛）の市場規模 ・世界の脱毛症治療薬（脱毛）市場規模：流通チャネル別 - 病院チャネルの市場規模 - 小売薬局チャネルの市場規模 - オンライン薬局チャネルの市場規模 ・世界の脱毛症治療薬（脱毛）市場規模：地域別 - 北米の脱毛症治療薬（脱毛）市場規模 アメリカの脱毛症治療薬（脱毛）市場規模 カナダの脱毛症治療薬（脱毛）市場規模 メキシコの脱毛症治療薬（脱毛）市場規模 … - ヨーロッパの脱毛症治療薬（脱毛）市場規模 ドイツの脱毛症治療薬（脱毛）市場規模 イギリスの脱毛症治療薬（脱毛）市場規模 フランスの脱毛症治療薬（脱毛）市場規模 … - アジア太平洋の脱毛症治療薬（脱毛）市場規模 中国の脱毛症治療薬（脱毛）市場規模 日本の脱毛症治療薬（脱毛）市場規模 インドの脱毛症治療薬（脱毛）市場規模 … - 南米/中東の脱毛症治療薬（脱毛）市場規模 ブラジルの脱毛症治療薬（脱毛）市場規模 アルゼンチンの脱毛症治療薬（脱毛）市場規模 サウジアラビアの脱毛症治療薬（脱毛）市場規模 … ・競争状況 ・市場機会・将来動向 |
Alopecia is a term used to describe excessive hair damage under certain medical conditions or dietary issues. A sedentary lifestyle and unhealthy diets are leading to loss of hair among masses. Furthermore, aging and hormonal imbalance, increasing chronic diseases like arthritis, cancer, hypertension, depression also leads to hair loss, especially among the middle-aged population. According to the American Hair Loss Association, androgenetic alopecia accounts for over 95% of hair loss in men. Over 800 thousand patients are seeking some kind of treatment for hair loss worldwide.
In recent years, many novel drugs have been approved by the regulatory bodies for the treatment of alopecia and many drugs are in pipeline, which are expected to receive approval in the near future. Concert Pharmaceuticals Inc. received fast track designation from the United States Food and Drug Administration, (FDA) for its novel product for the treatment of moderate-to-severe alopecia areata in January 2018. The launches of such novel products in the market is expected to drive the global alopecia treatment market growth in the near future.
Alopecia Treatment (Hair Loss) Market Trends
Female is Expected to Hold Largest Share Over the forecast period
About one-third of women experience hair loss (alopecia) at some time in their lives. Among postmenopausal women, as many as two-thirds suffer hair thinning or bald spots. Hair loss in women often has a greater impact than hair loss does on men, because it’s less socially acceptable for them.
Androgenetic alopecia is the most common cause of hair loss in women. Alopecia can severely affect a woman’s emotional well-being and quality of life. Although Alopecia is more common in male than female, the female has the largest share in the market owing to the factors such as high awareness levels coupled with increased frequency of Polycystic Ovary Syndrome (PCOS) causing a hormonal imbalance that leads to androgenetic alopecia.
North America Region Holds the Largest Market Share of Alopecia Treatment (Hair Loss) Market
North America dominates the Alopecia Treatment (Hair Loss) market due to the presence of technologically advanced healthcare infrastructure, high disposable income, and availability of novel therapeutics options pertaining to the treatments. According to the United States National Library of Medicine, Alopecia areata affects 1 in every 500 to 1,000 people in the United States. It is one of many recognized forms of alopecia, alopecia areata is the second most common form after androgenetic alopecia. Alopecia areata affects men and women equally, and it can occur in people of any ethnic background. Therefore, the high prevalence and the proportionally high treatment rates pertaining to hair loss in the U.S. are high major drivers for the North American market.
Alopecia Treatment (Hair Loss) Market Competitor Analysis
Some of the prominent industry players operating in total Alopecia Treatment (Hair Loss) market include Sun Pharmaceuticals Industries Ltd., Aclaris Therapeutics Inc., Cipla Inc., Concert Pharmaceuticals Inc., Daiichi Sankyo Inc. The development of advanced products for better outcomes and rigorous marketing is one of the competitive strategies adopted by the market players. In 2018, HCell Inc., a biotechnology company received orphan drug designation (ODD) for its product from the FDA. Furthermore, in 2017, Perrigo Company PLC. Launched over-the-counter Women’s Rogaine, which helps to regrow hair on top of the scalp.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Alopecia
4.2.2 Increasing R&D Initiatives and New Product Launches and Approvals
4.3 Market Restraints
4.3.1 Patent Expiry of Many Blockbuster Drugs
4.3.2 Side Effects Associated with the Available Hair Loss Treatment Therapies
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Disease Type
5.1.1 Androgenic Alopecia
5.1.2 Alopecia Areata
5.1.3 Ciatricial Alopecia
5.1.4 Traction Alopecia
5.1.5 Alopecia Totalis
5.2 By Gender
5.2.1 Male
5.2.2 Female
5.3 By Route of Administration
5.3.1 Oral
5.3.2 Topical
5.3.3 Injectable
5.4 By Distribution Channel
5.4.1 Hospitals
5.4.2 Retail Pharmacies
5.4.3 Online Pharmacies
5.5 Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle-East
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle-East
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Aclaris Therapeutics Inc.
6.1.2 Cipla Inc.
6.1.3 Concert Pharmaceuticals Inc.
6.1.4 Daiichi Sankyo Inc.
6.1.5 GlaxoSmithKline PLC
6.1.6 HCell Inc.
6.1.7 Johnson & Johnson
6.1.8 Merck & Co. Inc.
6.1.9 Sun Pharmaceuticals Industries Ltd
7 MARKET OPPORTUNITIES AND FUTURE TRENDS